1. Home
  2. Clinical Topics
  3. Cardio-Pulmonary
  4. Off-label use of recombinant activated factor VII increases risk of arterial events
Cardio-PulmonaryClinical TopicsDrugs and DevicesWeb Exclusives

Off-label use of recombinant activated factor VII increases risk of arterial events

Share

Off-label use of recombinant activated factor VII (rFVIIa) increases the risk of arterial but not venous thromboembolic events, particularly in older patients, according to an analysis of randomized clinical trials in the New England Journal of Medicine. Read more here.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts